Back to News
Market Impact: 0.15
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026
Source: GlobeNewswire
Healthcare & BiotechProduct Launches
Poster presentations provided additional characterization of HLP003's clinical profile and outlined the Phase 3 PARADIGM program evaluating it as an adjunctive treatment for major depressive disorder. The update signals continued late-stage clinical development, but includes no efficacy, safety, regulatory, or financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- GRAIL Stock Bounces Back Above $100: Can Galleri Sail Through Its FDA Panel Review?
- Meta's Muse personal AI agent tops ChatGPT, Grok and Claude for post-launch downloads
- Muse, Meta's extraordinarily privileged AI assistant, has a serious 0-day
- Ra Capital Management sells $21.8m in Sionna Therapeutics shares
- Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
- Why is Labcorp stock sliding today?